DandD Pharmatech Revenue and Competitors
Estimated Revenue & Valuation
- DandD Pharmatech's estimated annual revenue is currently $1.7M per year.
- DandD Pharmatech's estimated revenue per employee is $100,500
- DandD Pharmatech's total funding is $2.2M.
Employee Data
- DandD Pharmatech has 17 Employees.
- DandD Pharmatech grew their employee count by -19% last year.
DandD Pharmatech's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and CEO | Reveal Email/Phone |
2 | Head Business Development D&D Pharmatech | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
DandD Pharmatech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $23.2M | 102 | -3% | N/A | N/A |
#2 | $1091M | 3777 | 3% | $982.6M | $7B |
#3 | $223.6M | 1118 | 80% | $100M | $2B |
What Is DandD Pharmatech?
D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers. Close collaborations with leading research institutes worldwide provide us with a unique opportunity to accelerate translation of cutting-edge research into revolutionary lifesaving therapeutic products for patients.
keywords:N/A
$2.2M
Total Funding
17
Number of Employees
$1.7M
Revenue (est)
-19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
DandD Pharmatech News
Akihiko Kondo and thousands of others are in devoted fictional relationships, served by a vast industry aimed at satisfying the desires of a...
A journal has retracted a 2021 paper claiming that vitamin D significantly reduced the inflammatory markers associated with COVID-19...
Other Companies in Seongnam-si
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 23 | 5% | N/A |
#2 | $2.8M | 29 | 61% | N/A |
#3 | $6.2M | 34 | 10% | N/A |
#4 | $7.1M | 46 | 12% | N/A |
#5 | $8.1M | 52 | -5% | N/A |